Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial

This cohort study examines whether consumption of a high-cannabidiol product resulted in detectable amounts of Δ9-tetrahydrocannabinol metabolites in the urine samples of participants.

Detalles Bibliográficos
Autores principales: Dahlgren, M. Kathryn, Sagar, Kelly A., Lambros, Ashley M., Smith, Rosemary T., Gruber, Staci A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429743/
https://www.ncbi.nlm.nih.gov/pubmed/33146684
http://dx.doi.org/10.1001/jamapsychiatry.2020.3567
_version_ 1784779553945681920
author Dahlgren, M. Kathryn
Sagar, Kelly A.
Lambros, Ashley M.
Smith, Rosemary T.
Gruber, Staci A.
author_facet Dahlgren, M. Kathryn
Sagar, Kelly A.
Lambros, Ashley M.
Smith, Rosemary T.
Gruber, Staci A.
author_sort Dahlgren, M. Kathryn
collection PubMed
description This cohort study examines whether consumption of a high-cannabidiol product resulted in detectable amounts of Δ9-tetrahydrocannabinol metabolites in the urine samples of participants.
format Online
Article
Text
id pubmed-9429743
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-94297432022-09-16 Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial Dahlgren, M. Kathryn Sagar, Kelly A. Lambros, Ashley M. Smith, Rosemary T. Gruber, Staci A. JAMA Psychiatry Research Letter This cohort study examines whether consumption of a high-cannabidiol product resulted in detectable amounts of Δ9-tetrahydrocannabinol metabolites in the urine samples of participants. American Medical Association 2020-11-04 2021-03 /pmc/articles/PMC9429743/ /pubmed/33146684 http://dx.doi.org/10.1001/jamapsychiatry.2020.3567 Text en Copyright 2020 Dahlgren MK et al. JAMA Psychiatry. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Dahlgren, M. Kathryn
Sagar, Kelly A.
Lambros, Ashley M.
Smith, Rosemary T.
Gruber, Staci A.
Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial
title Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial
title_full Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial
title_fullStr Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial
title_full_unstemmed Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial
title_short Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial
title_sort urinary tetrahydrocannabinol after 4 weeks of a full-spectrum, high-cannabidiol treatment in an open-label clinical trial
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429743/
https://www.ncbi.nlm.nih.gov/pubmed/33146684
http://dx.doi.org/10.1001/jamapsychiatry.2020.3567
work_keys_str_mv AT dahlgrenmkathryn urinarytetrahydrocannabinolafter4weeksofafullspectrumhighcannabidioltreatmentinanopenlabelclinicaltrial
AT sagarkellya urinarytetrahydrocannabinolafter4weeksofafullspectrumhighcannabidioltreatmentinanopenlabelclinicaltrial
AT lambrosashleym urinarytetrahydrocannabinolafter4weeksofafullspectrumhighcannabidioltreatmentinanopenlabelclinicaltrial
AT smithrosemaryt urinarytetrahydrocannabinolafter4weeksofafullspectrumhighcannabidioltreatmentinanopenlabelclinicaltrial
AT gruberstacia urinarytetrahydrocannabinolafter4weeksofafullspectrumhighcannabidioltreatmentinanopenlabelclinicaltrial

Ejemplares similares